Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Legislation

Latest From Legislation

French Regulator Wants More Trial Sponsors To Take Part In Pilot Of Future EU Procedures

A French pilot project testing out the future EU clinical trial authorization procedures has borne fruit after the first two years, but the regulator wants many more sponsors to use the pilot so that the country is ready for the new rules in 2019.

Clinical Trials France

HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority

Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.

Pricing Debate Government Payers

Battlefield Emergency Use Bill Faces Pushback From US FDA, Authorizing Committees

Top Republicans on FDA authorizing committees worry that undermining agency's sole authority to approve drugs and devices would bring more harm than good.

Legislation Drug Review

Congress Crafting Bill To Modify Patent Challenges In Wake Of Allergan-Mohawk Deal

House IP Subcommittee Chair Issa suggests legislation may address sovereign immunity and ways to make inter partes review process more palatable to patent owners.

Intellectual Property Legal Issues

Orphan Drug Pricing Doesn't Drive Healthcare Costs, NORD Argues

QuintilesIMS Institute study funded by the National Organization for Rare Disorders concludes orphan drugs accounted for only 7.9% of US total drug spending in 2016, bolstering advocacy group's view that rare disease treatments are not responsible for rising healthcare costs. US FDA analysis finds most orphan drugs do not expand their labeled indications into non-rare disease settings.

Rare Diseases Legislation

Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?

PhRMA is stepping up its advocacy for 340B reform, noting recent reduction in Medicare payments for 340B is encouraging in that it indicates Administration may be open to further change.

Pricing Debate Medicare
See All